Accentia Biopharmaceuticals, Inc. to Present at The Wall Street Analyst Forum.TAMPA, Fla. -- Accentia Biopharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ABPI ABPI Association of the British Pharmaceutical Industry ABPI Associação Brasileira da Propriedade Intelectual (Brazilian Intellectual Property Association; Brazil) ABPI Ankle Brachial Pressure Index ), a biopharmaceutical company focused on the development and commercialization of late-stage clinical respiratory and oncological products, will present at The Wall Street Analyst Forum at New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of City's Princeton Club The Princeton Club of New York is a social organization in New York City catering to faculty and alumni of Princeton University in Princeton, New Jersey. Incorporated on Dec. 7, 1899, the club has had four homes before settling into its current clubhouse at 15 W. Monday, February 27, 2006. Frank E. O'Donnell, Jr., M.D., Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , will address attendees at 1:20 PM and hold a break-out session at 2:00 PM. Members of the investment community, the media and other interested parties can access a live audio webcast of Accentia's presentation by accessing the following link: http://www.investorcalendar.com/CEPage.asp?ID=100025. The presentation will be available and archived for 30 days in the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of Accentia's website: www.accentia.net. More than 50 companies from a variety of sectors will present at the Forum. Analysts and portfolio managers are invited to attend the conference at no cost. About The Wall Street Analyst Forum Since 1988, The Wall Street Analyst Forum (WSAF WSAF Warwick Student Arts Festival (University of Warwick; UK) ) has organized 75 major analyst conferences for NYSE/NASDAQ/AMEX corporations in New York, Boston and London. Over 2,500 public large-cap, mid-cap and small-cap corporations from all sectors have presented at the conference. Analyst/portfolio managers from a vast majority of money management firms attend the conferences either in person or via webcast. The WSAF hosts four annual analyst conferences, each incorporating the CEO's/CFO's of 50-60 presenting corporations. The WSAF is a member of the CFA Institute and the Professional Association of Analysts/Portfolio Managers. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. Two of these products are SinuNase(TM) and BiovaxID. The Company's SinuNase(TM) product, in development to treat chronic sinusitis chronic sinusitis Chronic sinus infection ENT Inflammation of the sinuses that empty into the nasal cavity Etiology Allergic rhinitis, nasal obstruction, deviated nasal septum, tooth abscesses, URIs (rhinosinusitis), is a novel application and formulation of a known anti-fungal licensed from the Mayo Foundation for Medical Education and Research. BiovaxID is a patient-specific anti-cancer vaccine focusing on the treatment of follicular fol·lic·u·lar adj. 1. Relating to, having, or resembling a follicle or follicles. 2. Affecting or growing out of a follicle or follicles. non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma . BiovaxID, which is being developed by Accentia's subsidiary Biovest International, Inc., is currently in a Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. . In addition, Accentia's growing specialty pharmaceutical business, TEAMM Pharmaceuticals, has a portfolio of currently marketed products plus a pipeline of additional products under development by third parties. For further information, please visit our web site: www.accentia.net. Forward-Looking Statements Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about BiovaxID and any other statements relating to products, product candidates, and product development programs. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia and/or Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward looking statements are qualified in their entirety by this cautionary statement, and neither Accentia nor Biovest undertakes any obligation to revise or update this news release to reflect events or circumstances after the date hereof. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion